

**Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2023-09-27 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

Pulmonary Arterial Hypertension Market Analysis and Insights

The Pulmonary Arterial Hypertension Market size is anticipated to reach USD 5.89 Billion in 2022 and it is projected to reach USD 9.53 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Pulmonary Arterial Hypertension Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Pulmonary Arterial Hypertension Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Pulmonary Arterial Hypertension Market includes major supplies & Independent Consultants among others.

Global Market Scope and Pulmonary Arterial Hypertension Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Pulmonary Arterial Hypertension Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Pulmonary Arterial Hypertension Market Country Level Analysis

The Global Pulmonary Arterial Hypertension Market Industry Analysis Research Report provides a basic overview of industry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

dominating market share expected 2024 to 2032. A detailed section on Pulmonary Arterial Hypertension Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Pulmonary Arterial Hypertension Market

Some of the other major highlights of the demand for Pulmonary Arterial Hypertension Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Pulmonary Arterial Hypertension Market during the forecast period.

Johnson and Johnson

Gilead Sciences Inc.

United Therapeutics Corporation

Accelaron Pharma, Inc.

GlaxoSmithKline plc (GSK)

Pfizer Inc.

Bayer AG.

#### Market Segmentation

The Global Pulmonary Arterial Hypertension Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Drug Class

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

ERA

PDE-5

#### Regions Coverd

##### North America

U.S.

Canada

##### Europe

U.K.

Germany

France

Spain

Italy

Russia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Nordic  
Benelux  
Rest of Europe

#### APAC

China  
Korea  
Japan  
India  
Australia  
Singapore  
Taiwan  
South East Asia  
Rest of Asia-Pacific

#### Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

#### LATAM

Brazil  
Mexico  
Argentina  
Chile  
Colombia  
Rest of LATAM

#### Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

#### Table of Contents:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators
  - 4.4 Geopolitical Impact
  - 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Pulmonary Arterial Hypertension Market Size Analysis
  - 6.1 By Drug Class
    - 6.1.1 Prostacyclin and Prostacyclin Analogs
    - 6.1.2 SGC Stimulators
    - 6.1.3 ERA
    - 6.1.4 PDE-5
- 7 North America Market Analysis
  - 7.1 By Drug Class
    - 7.1.1 Prostacyclin and Prostacyclin Analogs
    - 7.1.2 SGC Stimulators
    - 7.1.3 ERA
    - 7.1.4 PDE-5
  - 7.1 U.S.
  - 7.2 Canada
- 8 Europe Market Analysis
  - 8.1 By Drug Class
    - 8.1.1 Prostacyclin and Prostacyclin Analogs
    - 8.1.2 SGC Stimulators
    - 8.1.3 ERA
    - 8.1.4 PDE-5
  - 8.1 U.K.
  - 8.2 Germany
  - 8.3 France
  - 8.4 Spain
  - 8.5 Italy
  - 8.6 Russia
  - 8.7 Nordic
  - 8.8 Benelux

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|                                                                     |  |
|---------------------------------------------------------------------|--|
| 8.9 Rest of Europe                                                  |  |
| 9 APAC Market Analysis                                              |  |
| 9.1 By Drug Class                                                   |  |
| 9.1.1 Prostacyclin and Prostacyclin Analogs                         |  |
| 9.1.2 SGC Stimulators                                               |  |
| 9.1.3 ERA                                                           |  |
| 9.1.4 PDE-5                                                         |  |
| 9.1 China                                                           |  |
| 9.2 Korea                                                           |  |
| 9.3 Japan                                                           |  |
| 9.4 India                                                           |  |
| 9.5 Australia                                                       |  |
| 9.6 Singapore                                                       |  |
| 9.7 Taiwan                                                          |  |
| 9.8 South East Asia                                                 |  |
| 9.9 Rest of Asia-Pacific                                            |  |
| 10 Middle East and Africa Market Analysis                           |  |
| 10.1 By Drug Class                                                  |  |
| 10.1.1 Prostacyclin and Prostacyclin Analogs                        |  |
| 10.1.2 SGC Stimulators                                              |  |
| 10.1.3 ERA                                                          |  |
| 10.1.4 PDE-5                                                        |  |
| 10.1 UAE                                                            |  |
| 10.2 Turkey                                                         |  |
| 10.3 Saudi Arabia                                                   |  |
| 10.4 South Africa                                                   |  |
| 10.5 Egypt                                                          |  |
| 10.6 Nigeria                                                        |  |
| 10.7 Rest of MEA                                                    |  |
| 11 LATAM Market Analysis                                            |  |
| 11.1 By Drug Class                                                  |  |
| 11.1.1 Prostacyclin and Prostacyclin Analogs                        |  |
| 11.1.2 SGC Stimulators                                              |  |
| 11.1.3 ERA                                                          |  |
| 11.1.4 PDE-5                                                        |  |
| 11.1 Brazil                                                         |  |
| 11.2 Mexico                                                         |  |
| 11.3 Argentina                                                      |  |
| 11.4 Chile                                                          |  |
| 11.5 Colombia                                                       |  |
| 11.6 Rest of LATAM                                                  |  |
| 12 Competitive Landscape                                            |  |
| 12.1 Global Pulmonary Arterial Hypertension Market Share By Players |  |
| 12.2 M & A Agreements & Collaboration Analysis                      |  |
| 13 Market Players Assessment                                        |  |
| 13.1 American International Industries (GIGI)                       |  |
| 13.1.1 Overview                                                     |  |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.1.2 Business Information
- 13.1.3 Revenue
- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 Gilead Sciences Inc.
- 13.3 United Therapeutics Corporation
- 13.4 Acceleron Pharma, Inc.
- 13.5 GlaxoSmithKline plc (GSK)
- 13.6 Pfizer Inc.
- 13.7 Bayer AG.
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2023-09-27 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License             | Price     |
|----------------|---------------------|-----------|
|                | Single User License | \$4500.00 |
|                | Global Site License | \$5500.00 |
|                |                     | VAT       |
|                |                     | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                                         |
|---------------|----------------------|-------------------------------|-----------------------------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |                                         |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2026-02-22"/> |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)